TELA Bio Files 8-K: Material Agreement & Financials

TL;DR

TELA Bio filed an 8-K for a new material agreement and financials.

AI Summary

On October 23, 2024, TELA Bio, Inc. filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the inclusion of financial statements and exhibits. Specific details regarding the agreement or financial figures were not provided in the header information.

Why It Matters

This filing indicates TELA Bio has entered into a significant agreement and is providing updated financial information, which could impact investor understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for a material definitive agreement and financial statements, without immediate negative or positive financial disclosures.

Key Players & Entities

• TELA Bio, Inc. (company) — Registrant
• October 23, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 1 Great Valley Parkway, Suite 24 (address) — Principal executive offices
• Malvern, Pennsylvania (location) — Principal executive offices location
• 19355 (zip_code) — Principal executive offices zip code
• 484-320-2930 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TELA Nasdaq Global Market
• $2.25 — nderwriters at a price to the public of $2.25 per share and (ii) pre-funded warrants
• $2.2499 — Warrants ") at a price to the public of $2.2499 per warrant, which represents the per s
• $0.0001 — offering price for the Shares less the $0.0001 per share exercise price for each such
• $37.3 million — fering are expected to be approximately $37.3 million after deducting the underwriting discou

Filing Documents

• tm2426723d1_8k.htm (8-K) — 35KB
• tm2426723d1_ex1-1.htm (EX-1.1) — 293KB
• tm2426723d1_ex4-1.htm (EX-4.1) — 70KB
• tm2426723d1_ex5-1.htm (EX-5.1) — 12KB
• tm2426723d1_ex5-1img001.jpg (GRAPHIC) — 6KB
• 0001104659-24-110891.txt ( ) — 685KB
• tela-20241023.xsd (EX-101.SCH) — 3KB
• tela-20241023_lab.xml (EX-101.LAB) — 33KB
• tela-20241023_pre.xml (EX-101.PRE) — 22KB
• tm2426723d1_8k_htm.xml (XML) — 4KB

01

Item 1.01 Entry into a Material Definitive Agreement. On October 23, 2024, TELA Bio, Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") by and between Canaccord Genuity LLC, as representative of the several underwriters named therein (the " Underwriters ") relating to the issuance and sale of an aggregate of (i) 12,000,000 shares (the " Firm Shares ") of the Company's common stock, par value $0.001 per share (the " Common Stock "), to the Underwriters at a price to the public of $2.25 per share and (ii) pre-funded warrants to purchase up to 5,800,000 shares of Common Stock (the " Pre-Funded Warrants ") at a price to the public of $2.2499 per warrant, which represents the per share public offering price for the Shares less the $0.0001 per share exercise price for each such Pre-Funded Warrant (the " Offering "). Pursuant to the terms of the Underwriting Agreement, the Company granted to the Underwriters a 30-day option to purchase up to an additional 2,670,000 shares of Common Stock in the Offering (the " Option Shares " and together with the Firm Shares, the " Shares "). The Offering is expected to close on October 24, 2024, subject to the satisfaction of customary closing conditions. All of the Shares and Pre-Funded Warrants in the Offering are being sold by the Company. The net proceeds to the Company from the Offering are expected to be approximately $37.3 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company may receive nominal proceeds, if any, from the exercise of the Pre-Funded Warrants. The Company intends to use the proceeds from the Offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures. The Pre-Funded Warrants are immediately exercisable, have an exercise price of $0.0001 and may b

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the amount of proceeds expected from the Offering, and the timing and certainty of completion of the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, the Company's ability to complete the Offering on favorable terms, or at all, as well as other risks detailed from time to time in the Company's filings with the SEC, including in its Annual Report on Form 10-K for the year ended December 31, 2023 and the Prospectus Supplement. These documents contain important factors that could cause actual results to differ from current expectations and from the forward-looking statements contained in this Current Report on Form 8-K. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 1.1 Underwriting Agreement, dated October 23, 2024, by and between TELA Bio, Inc. and Canaccord Genuity LLC. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELA BIO, INC. By: /s/ Antony Koblish Name: Antony Koblish Title: President, Chief Executive Officer and Director Date: October 23, 2024

View Full Filing

View this 8-K filing on SEC EDGAR